Objectives: The use of benzalkonium chloride (BAC)-preserved medications is associated
with ocular surface disease (OSD) that can negatively affect quality of life (QoL) in glaucoma …

Aim. The purpose of this study is to evaluate and compare the efficacy of 4 prostaglandin
analogues (PGAs) and to determine the incidence of ocular surface disease in newly …

Purpose The preservative benzalkonium chloride (BAK) may adversely affect ocular surface
health. This study evaluated symptoms of ocular surface disease (OSD) in patients …

Purpose. Primary open‐angle glaucoma (POAG), a chronic, degenerative optic neuropathy,
requires persistent decrease of intraocular pressure so as to prevent visual impairment and …

Introduction. The topical medications containing benzalkonium chloride (BAK) as
preservative is known to induce corneal toxicity and ocular surface disease (OSD) in …

Purpose To assess the efficacy and tolerability of benzalkonium chloride (BAK)-free
travoprost after transition from BAK-preserved latanoprost. Methods This was a prospective …

Purpose: To assess a change in visual-related quality of life (QoL) in glaucoma patients after
switching from preservative-containing medical therapy to preservative-free unit dose …

PURPOSE: To investigate the relationship between ocular surface disease and glaucoma-
related quality of life (QoL), glaucoma severity, and treatment in patients with open-angle …

Purpose To assess the quality of life of glaucoma patients under medical therapy with
different prostaglandin analogs. Methods A cross-sectional study of consecutive glaucoma …

Background To compare the effect of two different prostaglandin analogues (Travatan® vs.
Xalatan®) on ocular surface parameters. Methods This study includes 44 eyes of 44 patients …